Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916306 | 0.82 | LOXL2 (0.59) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL9219228 | 0.81 | LOXL2 (0.58) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL1758645 | 0.81 | LOXL2 (0.58) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL28741620 | 0.80 | ALDH1A1 (0.59) | MAPTALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL73418 | 0.80 | LOXL2 (0.53) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL915436 | 0.80 | LOXL2 (0.53) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL131711 | 0.79 | LOXL2 (0.70) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL2208162 | 0.79 | LOXL2 (0.51) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 | |
| SCHEMBL8220530 | 0.79 | PLA2G10 (0.47) | MAPTALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL914841 | 0.78 | LOXL2 (0.54) | LOXL2MAPTCYP4A11CYP4F2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7189702-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-7087579-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2006-06-29 | — | — | US | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | SLC5A2, SLC5A1, SLC2A1 | LOXL2 4306/4885MAPT 2110/4885CYP4A11 306/4885 |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | SLC5A2, SLC5A1, UGGT1 | LOXL2 4131/4885MAPT 1687/4885CYP4A11 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.